189 related articles for article (PubMed ID: 38113256)
1. Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
Zhao Z; Aoi Y; Philips CN; Meghani KA; Gold SR; Yu Y; John LS; Qian J; Zeidner JM; Meeks JJ; Shilatifard A
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2310063120. PubMed ID: 38113256
[TBL] [Abstract][Full Text] [Related]
2. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers.
Hu D; Gao X; Morgan MA; Herz HM; Smith ER; Shilatifard A
Mol Cell Biol; 2013 Dec; 33(23):4745-54. PubMed ID: 24081332
[TBL] [Abstract][Full Text] [Related]
3. Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E; Jang Y; Ge K
Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
[TBL] [Abstract][Full Text] [Related]
4. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Wang LH; Aberin MAE; Wu S; Wang SP
Biochem Soc Trans; 2021 Jun; 49(3):1041-1054. PubMed ID: 34156443
[TBL] [Abstract][Full Text] [Related]
5. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
6. An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells.
Cao K; Collings CK; Morgan MA; Marshall SA; Rendleman EJ; Ozark PA; Smith ER; Shilatifard A
Sci Adv; 2018 Jan; 4(1):eaap8747. PubMed ID: 29404406
[TBL] [Abstract][Full Text] [Related]
7. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.
Wang SP; Tang Z; Chen CW; Shimada M; Koche RP; Wang LH; Nakadai T; Chramiec A; Krivtsov AV; Armstrong SA; Roeder RG
Mol Cell; 2017 Jul; 67(2):308-321.e6. PubMed ID: 28732206
[TBL] [Abstract][Full Text] [Related]
8. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.
Kim JH; Sharma A; Dhar SS; Lee SH; Gu B; Chan CH; Lin HK; Lee MG
Cancer Res; 2014 Mar; 74(6):1705-17. PubMed ID: 24491801
[TBL] [Abstract][Full Text] [Related]
9. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation.
Lee JE; Wang C; Xu S; Cho YW; Wang L; Feng X; Baldridge A; Sartorelli V; Zhuang L; Peng W; Ge K
Elife; 2013 Dec; 2():e01503. PubMed ID: 24368734
[TBL] [Abstract][Full Text] [Related]
10. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Dhar SS; Lee MG
Oncotarget; 2021 Jun; 12(13):1296-1308. PubMed ID: 34194626
[TBL] [Abstract][Full Text] [Related]
11. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.
Wang C; Lee JE; Lai B; Macfarlan TS; Xu S; Zhuang L; Liu C; Peng W; Ge K
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11871-11876. PubMed ID: 27698142
[TBL] [Abstract][Full Text] [Related]
12. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.
Rahnamoun H; Hong J; Sun Z; Lee J; Lu H; Lauberth SM
J Biol Chem; 2018 Aug; 293(34):13234-13246. PubMed ID: 29954944
[TBL] [Abstract][Full Text] [Related]
14. Kabuki syndrome stem cell models reveal locus specificity of histone methyltransferase 2D (KMT2D/MLL4).
Jefri M; Zhang X; Stumpf PS; Zhang L; Peng H; Hettige N; Theroux JF; Aouabed Z; Wilson K; Deshmukh S; Antonyan L; Ni A; Alsuwaidi S; Zhang Y; Jabado N; Garcia BA; Schuppert A; Bjornsson HT; Ernst C
Hum Mol Genet; 2022 Oct; 31(21):3715-3728. PubMed ID: 35640156
[TBL] [Abstract][Full Text] [Related]
15. The histone methyltransferase KMT2D, mutated in Kabuki syndrome patients, is required for neural crest cell formation and migration.
Schwenty-Lara J; Nehl D; Borchers A
Hum Mol Genet; 2020 Jan; 29(2):305-319. PubMed ID: 31813957
[TBL] [Abstract][Full Text] [Related]
16. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4.
Dhar SS; Lee SH; Kan PY; Voigt P; Ma L; Shi X; Reinberg D; Lee MG
Genes Dev; 2012 Dec; 26(24):2749-62. PubMed ID: 23249737
[TBL] [Abstract][Full Text] [Related]
17. H3K4 Methyltransferase Activity Is Required for MLL4 Protein Stability.
Jang Y; Wang C; Zhuang L; Liu C; Ge K
J Mol Biol; 2017 Jun; 429(13):2046-2054. PubMed ID: 28013028
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of histone 3 methyltransferase MLL4].
Guo HH; Lu SF; Cai Y; Liu SB; Zhu BM
Sheng Li Xue Bao; 2019 Aug; 71(4):637-644. PubMed ID: 31440761
[TBL] [Abstract][Full Text] [Related]
19. The KMT2D Kabuki syndrome histone methylase controls neural crest cell differentiation and facial morphology.
Shpargel KB; Mangini CL; Xie G; Ge K; Magnuson T
Development; 2020 Jul; 147(21):. PubMed ID: 32541010
[TBL] [Abstract][Full Text] [Related]
20. Modus operandi of COMPASS/MLL epigenetic writers in the mammalian genome.
Bayarsaihan D
Epigenomics; 2018 Jul; 10(7):861-863. PubMed ID: 29956546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
